Pneumococcal conjugate second or third-dose vaccines (PCVc) in Niger
Niger: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 87.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Niger, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Niger recorded 87.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
Compared with earlier readings it is up 1.2% on the previous year and up 77.6% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Niger peaked at 87.0% in 2025 and was at its lowest, 0.0%, in 2008.
That places Niger 86th out of 194 countries with data for 2025, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Niger, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 13.0% | — |
| 2015 | 49.0% | +276.9% |
| 2016 | 76.0% | +55.1% |
| 2017 | 85.0% | +11.8% |
| 2018 | 79.0% | -7.1% |
| 2019 | 81.0% | +2.5% |
| 2020 | 81.0% | +0.0% |
| 2021 | 82.0% | +1.2% |
| 2022 | 84.0% | +2.4% |
| 2023 | 85.0% | +1.2% |
| 2024 | 86.0% | +1.2% |
| 2025 | 87.0% | +1.2% |
Niger compared with similar countries
- Niger's 87.0% is above the median for low income countries, which is 80.0%, 1.1× the median. (25 countries reporting)
- Niger's 87.0% is above the median for Sub-Saharan Africa, which is 82.5%, 1.1× the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 38.3% | 0.0% | 85.0% | 10 |
| 2020s | 84.2% | 81.0% | 87.0% | 6 |
Countries ranked near Niger
- 86 Kenya 87.0% compare
- 86 Kiribati 87.0% compare
- 86 Dominican Republic 87.0% compare
- 86 Netherlands 87.0% compare
- 86 Lithuania 87.0% compare
More health data for Niger
- Un projection of annual infant deaths, annual growth rate -1.58 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.35 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 887.5 deaths per 1,000 people (2090)
- Number of infants who die before age 1 22,995 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 15 (2025)
- Population ages 00-04, female, annual growth rate 2.54 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0865 units per person (2025)
- Population ages 00-04, male, annual growth rate 2.53 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Niger?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Niger was 87.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Niger?
- The highest recorded value was 87.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Niger?
- The lowest recorded value was 0.0% in 2008.
- How does Niger rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Niger ranks 86th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Niger?
- Over the last ten years it is up 77.6%. The long-run trend across the full record is volatile.
- Where does this Niger data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).